TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29999537

Group type: EXPERIMENTAL
Intervention: Photographic intervention method (taking photos and writing expressively)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Taking-photos-only control
Number of subjects: 145

Group type: COMPARATOR
Intervention: Assessment-only control
Number of subjects: 145
Study: 29258928

Group type: EXPERIMENTAL
Intervention: Total intravenous anesthesia
Number of subjects: 106

Group type: COMPARATOR
Intervention: Combined intravenous‐inhalation anesthesia
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: FMEP ratio cut-off values of 77.4%
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: FMEP ratio cut-off values of 56.9%
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: FMEP ratio ≥57%
Number of subjects: 106
Study: 27725652

Group type: EXPERIMENTAL
Intervention: Low FODMAP diet
Number of subjects: 92

Group type: COMPARATOR
Intervention: mNICE diet
Number of subjects: 92
Study: 24503517

Group type: EXPERIMENTAL
Intervention: VIPS practice model (VPM)
Number of subjects: 0
Study: 22648471

Group type: EXPERIMENTAL
Intervention: External focus of attention (EXF)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Internal focus (INF)
Number of subjects: 36
Study: 19438670

Group type: EXPERIMENTAL
Intervention: Neodymium-doped yttrium aluminium garnet (Nd:YAG) laser treatment
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control sites (not treated with Nd:YAG laser)
Number of subjects: 22
Study: 17486027

Group type: EXPERIMENTAL
Intervention: Activated device treatment for 10 minutes (PDE study)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Activated device treatment for 10 minutes (SS study)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group (no treatment) in PDE study
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group (no treatment) in SS study
Number of subjects: 55
Study: 16382002

Group type: EXPERIMENTAL
Intervention: Methyltestosterone (MT) (1.25 mg/day) combined with percutaneous estradiol (E2) (1 mg/day)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo combined with percutaneous estradiol (E2) (1 mg/day)
Number of subjects: 37
Study: 12678188

Group type: EXPERIMENTAL
Intervention: Compression stockings (Kendall Travel Socks) providing 20-30 mm Hg pressure at the ankle
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (no stockings)
Number of subjects: 150
Study: 10781751

Group type: COMPARATOR
Intervention: ASA alone
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: ASA + ticlopidine
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: ASA + cilostazol
Number of subjects: 36
Study: 8640706

Group type: EXPERIMENTAL
Intervention: Adjuvant Active Specific Immunotherapy (ASI) with 3 intradermal injections of 10^7 autologous irradiated tumor cells mixed with 10^7 Bacillus Calmette‐Guèrin
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (nonimmunized patients)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Adjuvant Active Specific Immunotherapy (ASI)
Number of subjects: 120
Study: 10149109

Group type: EXPERIMENTAL
Intervention: ioversol-350
Number of subjects: 80

Group type: COMPARATOR
Intervention: iohexol-350
Number of subjects: 80
Study: 6874972

Group type: EXPERIMENTAL
Intervention: Rational Stage Directed Hypnotherapy (RSDH)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Hypnosis-only treatment
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo condition
Number of subjects: 48

Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 48
Study: 30630401

Group type: EXPERIMENTAL
Intervention: Self-directed care
Number of subjects: 216

Group type: COMPARATOR
Intervention: Services as usual
Number of subjects: 216
Study: 30417648

Group type: EXPERIMENTAL
Intervention: Ibuprofen immediate-release (IR) tablet
Number of subjects: 17
Study: 26477395

Group type: EXPERIMENTAL
Intervention: (18)F‐FDG‐PET based workup strategy (PWU)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Conventional workup strategy (CWU)
Number of subjects: 150
Study: 24264638

Group type: EXPERIMENTAL
Intervention: SuperBond‐C&B
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Panavia F
Number of subjects: 60

Group type: COMPARATOR
Intervention: Ketac Cem (glass ionomer)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ketac Cem
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: All cement types
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 60
Study: 22146754

Group type: EXPERIMENTAL
Intervention: 10.0 mm tip-ring electrode spacing
Number of subjects: 31

Group type: COMPARATOR
Intervention: 1.1 mm tip-ring electrode spacing
Number of subjects: 31
Study: 19158317

Group type: EXPERIMENTAL
Intervention: Rosuvastatin (10 mg daily for 4 weeks)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (16 hypercholesterolemic patients)
Number of subjects: 32
Study: 17685686

Group type: EXPERIMENTAL
Intervention: Active Dynamic Stretch (ADS)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Static Passive Stretch combined with Active Dynamic Stretch (SADS)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Static Dynamic Stretch combined with Active Dynamic Stretch (DADS)
Number of subjects: 18
Study: 16368585

Group type: EXPERIMENTAL
Intervention: 10% lignocaine spray
Number of subjects: 58

Group type: COMPARATOR
Intervention: 2% lignocaine jelly
Number of subjects: 58
Study: 11893233

Group type: EXPERIMENTAL
Intervention: Prolonged-release alfuzosin 10mg once daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Immediate-release alfuzosin 2.5mg three times daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10442900

Group type: EXPERIMENTAL
Intervention: ABCR gene variants screening in AMD population
Number of subjects: 212

Group type: COMPARATOR
Intervention: Control group (56 individuals with no known history of AMD)
Number of subjects: 212
Study: 8657319

Group type: EXPERIMENTAL
Intervention: Primary angioplasty
Number of subjects: 301

Group type: COMPARATOR
Intervention: Intravenous streptokinase
Number of subjects: 301
Study: 2138176

Group type: EXPERIMENTAL
Intervention: 4% erythromycin plus 1.2% zinc acetate
Number of subjects: 73

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 73
Study: 7357232

Group type: EXPERIMENTAL
Intervention: Experimental treatment (conversation training programme)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Behavioural treatment control
Number of subjects: 0

Group type: COMPARATOR
Intervention: Attention control group
Number of subjects: 0
Study: 31604496

Group type: EXPERIMENTAL
Intervention: Suture Bridge (SB) technique
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Medially Based Single-Row (medSR) technique
Number of subjects: 92

Group type: COMPARATOR
Intervention: Comparison of SB and medSR techniques
Number of subjects: 92
Study: 29166185

Group type: EXPERIMENTAL
Intervention: Parental holding and an upright position
Number of subjects: 34
Study: 26188879

Group type: EXPERIMENTAL
Intervention: 25mg etanercept
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 23388517

Group type: EXPERIMENTAL
Intervention: Custom-made lipid- and protein-rich nutrition
Number of subjects: 18

Group type: COMPARATOR
Intervention: Isocaloric control nutrition
Number of subjects: 18
Study: 21492412

Group type: EXPERIMENTAL
Intervention: Web-based brief alcohol intervention (N=454)
Number of subjects: 908

Group type: COMPARATOR
Intervention: No intervention (Control) (N=454)
Number of subjects: 908
Study: 19681767

Group type: EXPERIMENTAL
Intervention: n-3 fatty acid supplementation for 5 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not n-3 supplemented burned group)
Number of subjects: 0
Study: 17605771

Group type: EXPERIMENTAL
Intervention: Multidisciplinary assessment and treatment of multifactorial fall risk factors.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 100
Study: 15646610

Group type: EXPERIMENTAL
Intervention: Oraqix anesthetic gel
Number of subjects: 337

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 337
Study: 11438048

Group type: EXPERIMENTAL
Intervention: Tectonic penetrating keratoplasty
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Tectonic sclerokeratoplasty
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (central penetrating keratoplasty for inactive central corneal scars)
Number of subjects: 60
Study: 9724256

Group type: EXPERIMENTAL
Intervention: Amitriptyline 50 mg for 21 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7831626

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroid (BA+CS)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Anticholinergic (BA+AC)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Placebo (BA+PL)
Number of subjects: 141
Study: 3207566

Group type: EXPERIMENTAL
Intervention: Sibutramine hydrochloride (60 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Amitriptyline (50 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Sibutramine hydrochloride
Number of subjects: 6
Study: 31597460

Group type: EXPERIMENTAL
Intervention: Higher-dose edoxaban regimen (60/30 mg daily)
Number of subjects: 21105

Group type: EXPERIMENTAL
Intervention: Lower-dose edoxaban regimen (30/15 mg daily)
Number of subjects: 21105

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 21105
Study: 28240714

Group type: EXPERIMENTAL
Intervention: 3% glycerol solution containing 26 ml·kg of water and 1 g·kg of glycerol
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control group drinking 26 ml·kg of water
Number of subjects: 7
Study: 26378819

Group type: EXPERIMENTAL
Intervention: Main error (ME) correction
Number of subjects: 22

Group type: COMPARATOR
Intervention: Secondary error (SE) correction
Number of subjects: 22
Study: 23562657

Group type: EXPERIMENTAL
Intervention: P-iTBS (sham intermittent theta burst stimulation)
Number of subjects: 26

Group type: COMPARATOR
Intervention: CON (no intervention)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: P-rTMS (sham high-frequency repetitive TMS)
Number of subjects: 26
Study: 22012943

Group type: EXPERIMENTAL
Intervention: Therapeutic music video intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treatment fidelity strategies
Number of subjects: 0
Study: 18835696

Group type: EXPERIMENTAL
Intervention: Pulmonary valve replacement (PVR)
Number of subjects: 58
Study: 16487205

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 102

Group type: COMPARATOR
Intervention: Ritodrine
Number of subjects: 102
Study: 14515286

Group type: EXPERIMENTAL
Intervention: TEA (thoracic epidural anaesthesia‐analgesia) with bupivacaine and fentanyl
Number of subjects: 38

Group type: COMPARATOR
Intervention: PCA (patient-controlled analgesia) with morphine
Number of subjects: 38
Study: 12669749

Group type: EXPERIMENTAL
Intervention: Salient distractor presented within 600 ms before the target
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Distractors presented at fixation
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Spatial shifts in attentional focus ruled out
Number of subjects: 7
Study: 10534571

Group type: EXPERIMENTAL
Intervention: CFS patients in target detection task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CFS patients in short-term memory task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CFS patients in memory task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CFS patients in self-paced movements and expectancy and reaction time (CNV) tasks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy normals
Number of subjects: 0
Study: 7705704

Group type: EXPERIMENTAL
Intervention: FUDR (22.5 mg/m2) and cisplatin (6.75 mg/m2) administered with concurrent whole pelvis radiation (40-50 Gy)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: FUDR and cisplatin regimen
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Dose level 4 (22.5 mg/m2 FUDR and 6.75 mg/m2 cisplatin)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Dose level 5 (27 mg/m2 FUDR and 8 mg/m2 cisplatin)
Number of subjects: 16
Study: 2649463

Group type: EXPERIMENTAL
Intervention: Misonidazole (MISO) 12 g/m2 applied within 6 weeks
Number of subjects: 331

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 331
Study: 73856

Group type: EXPERIMENTAL
Intervention: Physiometrics automatic blood-pressure recorder
Number of subjects: 0

Group type: COMPARATOR
Intervention: Direct recordings
Number of subjects: 0
Study: 29621894

Group type: EXPERIMENTAL
Intervention: Clinic delivery of the Lidcombe Program
Number of subjects: 49

Group type: COMPARATOR
Intervention: Telehealth delivery of the Lidcombe Program
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Both interventions (Clinic and Telehealth)
Number of subjects: 49
Study: 27882399

Group type: EXPERIMENTAL
Intervention: Polysomnography night
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: CPAP titration night
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: ESS
Number of subjects: 97
Study: 26010727

Group type: EXPERIMENTAL
Intervention: Esperanza y Vida program delivered by lay health advisor cancer survivors
Number of subjects: 908
Study: 23473794

Group type: EXPERIMENTAL
Intervention: Plasma phospholipid 16:0
Number of subjects: 1576
Study: 21277706

Group type: EXPERIMENTAL
Intervention: Waterpipe tobacco smoking
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo (flavor-matched, tobacco-free preparation)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Waterpipe tobacco smoking and Placebo
Number of subjects: 37
Study: 19591885

Group type: EXPERIMENTAL
Intervention: Gruel made from instant infant flour
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Gruel made from food supplement containing amylases
Number of subjects: 144

Group type: COMPARATOR
Intervention: Home-made complementary foods
Number of subjects: 144
Study: 17728549

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Various treatment approaches (laser photocoagulation, PDT, subretinal surgery, novel anti-angiogenic drugs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Case series and individual case control studies
Number of subjects: 0
Study: 15139406

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/day
Number of subjects: 4914

Group type: COMPARATOR
Intervention: Pravastatin 40 mg/day
Number of subjects: 4914
Study: 11230490

Group type: EXPERIMENTAL
Intervention: Myocet (liposome-encapsulated doxorubicin) + cyclophosphamide
Number of subjects: 297

Group type: COMPARATOR
Intervention: Conventional doxorubicin + cyclophosphamide
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: Myocet + cyclophosphamide
Number of subjects: 297
Study: 9988986

Group type: EXPERIMENTAL
Intervention: Anorectic patients
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Recovering anorectics
Number of subjects: 114

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 114
Study: 7995624

Group type: EXPERIMENTAL
Intervention: Insulin infusion (to raise plasma insulin 100 microU/mL)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Insulin infusion
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 9
Study: 3294036

Group type: EXPERIMENTAL
Intervention: Slow-release terbutaline (b.i.d. 0.25 mg/kg per day)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Slow-release theophylline (5.31 mg/kg morning and 10.62 mg/kg evening)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Slow-release theophylline
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Slow-release terbutaline
Number of subjects: 11
Study: 30799231

Group type: EXPERIMENTAL
Intervention: OM3-PL/FFA
Number of subjects: 56

Group type: COMPARATOR
Intervention: OM3-EE
Number of subjects: 56
Study: 27918705

Group type: EXPERIMENTAL
Intervention: Whole-body vibration training (WBVT)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Nonexercising control group
Number of subjects: 27
Study: 25846661

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 106

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 106
Study: 23656810

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) + drug group
Number of subjects: 133

Group type: COMPARATOR
Intervention: Drug group (mometasone furoate nasal spray and desloratadine tablets)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Drug group
Number of subjects: 133
Study: 22188590

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate (FF) 200 μg once daily (OD)
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate (FF) 100 μg twice daily (BD)
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 200 μg OD
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 100 μg BD
Number of subjects: 190

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 190
Study: 19414836

Group type: EXPERIMENTAL
Intervention: Flexible-duration, ultrasonography-guided anticoagulation
Number of subjects: 538

Group type: COMPARATOR
Intervention: Fixed-duration anticoagulation
Number of subjects: 538

Group type: EXPERIMENTAL
Intervention: Flexible-duration, ultrasonography-guided anticoagulation (for unprovoked DVT)
Number of subjects: 538

Group type: EXPERIMENTAL
Intervention: Flexible-duration, ultrasonography-guided anticoagulation (for secondary DVT)
Number of subjects: 538
Study: 17061440

Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation (nutritional doses)
Number of subjects: 5086

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5086
Study: 14690730

Group type: EXPERIMENTAL
Intervention: ONCAB surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: OFFCAB surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgery (both ONCAB and OFFCAB)
Number of subjects: 0
Study: 11712619

Group type: EXPERIMENTAL
Intervention: Amisulpride (50 mg o.d.)
Number of subjects: 313

Group type: COMPARATOR
Intervention: Sertraline (50‐100 mg o.d.)
Number of subjects: 313
Study: 9446006

Group type: EXPERIMENTAL
Intervention: Diltiazem (I, n = 17)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Nifedipine (II, n = 17)
Number of subjects: 51

Group type: COMPARATOR
Intervention: No calcium channel blockers (III, n = 17)
Number of subjects: 51
Study: 11548224

Group type: EXPERIMENTAL
Intervention: Glucosamine sulfate 500 mg t.i.d. for 4 weeks
Number of subjects: 252

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 252
Study: 3074291

Group type: EXPERIMENTAL
Intervention: Oxitropium bromide at 600 micrograms (6 subjects)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Oxitropium bromide at 400 micrograms t.i.d. (6 subjects)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Slow-release theophylline at 300 mg b.i.d. (11 subjects)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Oxitropium bromide (both dosages)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Slow-release theophylline
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Oxitropium bromide
Number of subjects: 23
Study: 31132111

Group type: EXPERIMENTAL
Intervention: FOLFOX + 2 g oral curcumin/d (CUFOX)
Number of subjects: 28

Group type: COMPARATOR
Intervention: FOLFOX
Number of subjects: 28
Study: 26818096

Group type: EXPERIMENTAL
Intervention: 15-mg mirtazapine (n = 8)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (n = 16)
Number of subjects: 24
Study: 25682769

Group type: EXPERIMENTAL
Intervention: Interferon-gamma release assay (IGRA)
Number of subjects: 807

Group type: COMPARATOR
Intervention: Tuberculin skin test (TST)
Number of subjects: 807

Group type: EXPERIMENTAL
Intervention: Quantiferon TB Gold (QFT-G)
Number of subjects: 807
Study: 23829057

Group type: EXPERIMENTAL
Intervention: Single dose of oral ivermectin 200 microg/kg body weight
Number of subjects: 440

Group type: COMPARATOR
Intervention: Two applications of topical lindane lotion 1% with a 1-week interval
Number of subjects: 440
Study: 21917377

Group type: EXPERIMENTAL
Intervention: Biopsychosocial training sessions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Biomechanics training sessions
Number of subjects: 0
Study: 18265647

Group type: EXPERIMENTAL
Intervention: OS‐1 (oral rehydration solution)
Number of subjects: 44

Group type: COMPARATOR
Intervention: KN3B (intravenous maintenance solution)
Number of subjects: 44
Study: 15119979

Group type: EXPERIMENTAL
Intervention: Risedronate 5 mg
Number of subjects: 2442
Study: 12960999

Group type: EXPERIMENTAL
Intervention: L-arginine (200 mg/kg infused intravenously over 4 hours, 12 and 3 hours before PCI, and 500 mg over 10 minutes prior to stent implantation, followed by oral supplementation of 6 g/day for 14 days after PCI)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 9689421

Group type: EXPERIMENTAL
Intervention: Isosorbide mononitrate (ISMN) 60 mg/d
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Pentaerithritol tetranitrate (PETN) 240 mg/d
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Pentaerithritol tetranitrate (PETN) 150 mg/d
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 7532087

Group type: EXPERIMENTAL
Intervention: High-dose aprotinin (6 million kallikrein inactivator units)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Low-dose aprotinin (3 million kallikrein inactivator units)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Low-dose aprotinin (3 million kallikrein inactivator units) with autologous blood transfusions
Number of subjects: 120
Study: 2673045

Group type: EXPERIMENTAL
Intervention: Sequential methotrexate-5-fluorouracil (MF)
Number of subjects: 133

Group type: COMPARATOR
Intervention: 5-fluorouracil alone (F)
Number of subjects: 133
Study: 28497259

Group type: EXPERIMENTAL
Intervention: Intravenous valproic acid (15 to 150 mg/kg)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 27598804

Group type: EXPERIMENTAL
Intervention: Long-term androgen deprivation (LTAD) combined with high-dose radiation therapy (HDRT)
Number of subjects: 355

Group type: COMPARATOR
Intervention: Short-term androgen deprivation (STAD) combined with high-dose radiation therapy (HDRT)
Number of subjects: 355
Study: 25457733

Group type: EXPERIMENTAL
Intervention: Web-delivered intervention (Young Adults Eating and Active for Health)
Number of subjects: 1639

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1639